Literature DB >> 11867941

Elevated expression of galanin receptors in childhood neuroblastic tumors.

Alexandra Berger1, Camilla Tuechler, Dietmar Almer, Per Kogner, Manfred Ratschek, Reinhold Kerbl, Tiina P Iismaa, Neil Jones, Wolfgang Sperl, Barbara Kofler.   

Abstract

The neuropeptide galanin (GAL) has been shown to be present in certain brain tumors. In order to learn more about GAL and its receptors in human tumors of the peripheral nervous system, we investigated the expression of the GAL peptide and the GAL receptors in tumor tissue from childhood neuroblastic tumors. GAL peptide concentrations up to 674 +/- 166 fmol/mg of tissue were detected by radioimmunoassay, but no significant correlation with standard tumor markers or the prognosis of the 14 patients investigated was observed. Ligand binding experiments showed different levels of GAL binding in all 28 primary neuroblastomas and 7 ganglioneuromas investigated. All three human GAL receptor subtypes cloned to date could be detected, with the GALR1 receptor subtype being expressed most prominently. GAL binding did not significantly correlate with genetic markers such as unfavorable DNA ploidy, amplification of the oncogene MYCN and allelic loss of chromosome 1p. However, low galanin binding was significantly correlated with survival (p = 0.021) in this limited analysis of neuroblastic tumor samples. These results raise the possibility that the expression of GAL binding sites may play a role in neuroblastic tumor biology and behavior. Copyright 2002 S. Karger AG, Basel

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 11867941     DOI: 10.1159/000048229

Source DB:  PubMed          Journal:  Neuroendocrinology        ISSN: 0028-3835            Impact factor:   4.914


  8 in total

1.  Epigenetic inactivation of galanin receptor 1 in head and neck cancer.

Authors:  Kiyoshi Misawa; Yo Ueda; Takeharu Kanazawa; Yuki Misawa; Ilwhan Jang; John Chadwick Brenner; Tetsuya Ogawa; Satoru Takebayashi; Reidar A Grenman; James G Herman; Hiroyuki Mineta; Thomas E Carey
Journal:  Clin Cancer Res       Date:  2008-12-01       Impact factor: 12.531

2.  Gangliocytes in neuroblastic tumors express alarin, a novel peptide derived by differential splicing of the galanin-like peptide gene.

Authors:  Radmila Santic; Katrin Fenninger; Kerstin Graf; Rainer Schneider; Cornelia Hauser-Kronberger; Freimut H Schilling; Per Kogner; Manfred Ratschek; Neil Jones; Wolfgang Sperl; Barbara Kofler
Journal:  J Mol Neurosci       Date:  2006       Impact factor: 3.444

3.  Expression of alarin in ependymoma and choroid plexus tumors.

Authors:  Nicole Eberhard; Serge Weis; Herbert Reitsamer; Barbara Kofler
Journal:  J Neurooncol       Date:  2013-06-13       Impact factor: 4.130

4.  Alarin is a vasoactive peptide.

Authors:  Radmila Santic; Sabine M Schmidhuber; Roland Lang; Isabella Rauch; Elena Voglas; Nicole Eberhard; Johann W Bauer; Susan D Brain; Barbara Kofler
Journal:  Proc Natl Acad Sci U S A       Date:  2007-05-29       Impact factor: 11.205

5.  Shared Copy Number Variation in Simultaneous Nephroblastoma and Neuroblastoma due to Fanconi Anemia.

Authors:  A Serra; K Eirich; A K Winkler; K Mrasek; G Göhring; G Barbi; H Cario; B Schlegelberger; B Pokora; T Liehr; C Leriche; D Henne-Bruns; T F Barth; D Schindler
Journal:  Mol Syndromol       Date:  2012-08-23

Review 6.  The Galaninergic System: A Target for Cancer Treatment.

Authors:  Manuel Lisardo Sánchez; Rafael Coveñas
Journal:  Cancers (Basel)       Date:  2022-08-01       Impact factor: 6.575

7.  Identifying candidate drivers of drug response in heterogeneous cancer by mining high throughput genomics data.

Authors:  Sheida Nabavi
Journal:  BMC Genomics       Date:  2016-08-15       Impact factor: 3.969

8.  Galanin System in Human Glioma and Pituitary Adenoma.

Authors:  Sarah Falkenstetter; Julia Leitner; Susanne M Brunner; Tim N Rieder; Barbara Kofler; Serge Weis
Journal:  Front Endocrinol (Lausanne)       Date:  2020-03-24       Impact factor: 5.555

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.